The suspension of Kazia Therapeutics' securities is a significant step towards its delisting from the ASX, which could indicate a strategic shift or other corporate actions that may affect investor confidence and the stock's liquidity. This typically has a negative short-term impact on a company's stock price as it may raise concerns among investors about the reasons behind the delisting and the future of the company.